Our top pick for
Building a portfolio
INmune Bio, Inc is a biotechnology business based in the US. INmune Bio shares (INMB) are listed on the NASDAQ and all prices are listed in US Dollars. INmune Bio employs 4 staff and has a market cap (total outstanding shares value) of USD$171.5 million.
|Latest market close||USD$10.22|
|52-week range||USD$2.2 - USD$16.25|
|50-day moving average||USD$9.175|
|200-day moving average||USD$9.1897|
|Wall St. target price||USD$20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.618|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||-58.99%|
|1 month (2020-12-24)||-19.84%|
|3 months (2020-10-22)||21.38%|
|6 months (2020-07-22)||-19.97%|
|1 year (2020-01-22)||94.66%|
|2 years (2019-01-20)||N/A|
|3 years (2018-01-20)||N/A|
|5 years (2016-01-20)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-20.8%|
|Return on equity TTM||-34.02%|
|Market capitalisation||USD$171.5 million|
TTM: trailing 12 months
There are currently 487,267 INmune Bio shares held short by investors – that's known as INmune Bio's "short interest". This figure is 9.4% down from 537,918 last month.
There are a few different ways that this level of interest in shorting INmune Bio shares can be evaluated.
INmune Bio's "short interest ratio" (SIR) is the quantity of INmune Bio shares currently shorted divided by the average quantity of INmune Bio shares traded daily (recently around 81482.775919732). INmune Bio's SIR currently stands at 5.98. In other words for every 100,000 INmune Bio shares traded daily on the market, roughly 5980 shares are currently held short.
However INmune Bio's short interest can also be evaluated against the total number of INmune Bio shares, or, against the total number of tradable INmune Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case INmune Bio's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 INmune Bio shares in existence, roughly 40 shares are currently held short) or 0.0526% of the tradable shares (for every 100,000 tradable INmune Bio shares, roughly 53 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against INmune Bio.
Find out more about how you can short INmune Bio stock.
We're not expecting INmune Bio to pay a dividend over the next 12 months.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.